Sensing " junk " RNA after chemotherapy enhances blood regeneration

(Max Planck Institute of Immunobiology and Epigenetics) Scientists from the MPI-IE reveal that during hematopoietic regeneration, RNA expressed from a part of the genome considered " junk DNA " is used by hematopoietic stem cells to get activated and proliferate. The study published in the scientific journal Nature Cell Biology shows that these so-called transposable elements make RNA after chemotherapy and activate an immune receptor which induces inflammatory signals enhancing hematopoietic stem cell cycling and thus participating in the regeneration of the hematopoietic system.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

in Li Tumors pose a significant threat to human health. Although many methods, such as operations, chemotherapy and radiotherapy, have been proposed to eliminate tumor cells, the results are unsatisfactory. Targeting therapy has shown potential due to its specificity and efficiency. Meanwhile, it has been revealed that cancer stem cells (CSCs) play a crucial role in the genesis, development, metastasis and recurrence of tumors. Thus, it is feasible to inhibit tumors and improve prognosis via targeting CSCs. In this review, we provide a comprehensive understanding of the biological characteristics of CSCs, including mit...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Prog Brain Res. 2021;265:99-118. doi: 10.1016/bs.pbr.2021.04.012. Epub 2021 Aug 12.ABSTRACTGlioblastoma multiforme (GBM) is an extremely aggressive primary human brain tumor. The median survival of GBM patients is 15 months in case of completing the modern complex treatment protocol. Chemotherapy can help to extend the life expectancy of patients. GBM treatment resistance is associated with cancer stem cells (CSCs). The present paper analyses the main reasons for ineffectiveness of the existing GBM treatment methods and suggests treating CSCs as a complex phenomenon, resulting from the coordinated interaction of normal ste...
Source: Brain Research - Category: Neurology Authors: Source Type: research
Clin Lymphoma Myeloma Leuk. 2021 Aug 20:S2152-2650(21)00361-X. doi: 10.1016/j.clml.2021.08.003. Online ahead of print.ABSTRACTPhiladelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) was historically considered to be a very poor-risk subtype of ALL. However, with the introduction of highly potent BCR-ABL tyrosine kinase inhibitors (TKIs), Ph+ ALL can now be considered relatively favorable-risk acute leukemia. Considering the high rates of measurable residual disease negativity and excellent long-term survival that has been achieved with regimens incorporating later-generation TKIs and particularly with ponat...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research
Conclusions: Our findings support chemotherapy-based regimens with early neutrophil engraftment, less ES and CMV reactivation compared with TBI. Although there is no impact on survival rates, increased incidence of ES and CMV reactivation should be considered in TBI-based regimens.
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Original Articles Source Type: research
Acute myeloid leukemia (AML) patients with high-risk disease benefit from allogeneic hematopoietic stem cell transplantation (allo-SCT) as consolidation therapy. Despite exhibiting a higher risk of non-relapse mortality (NRM) than conventional chemotherapy, allo-transplanted patients experience lower relapse rates due to the pre-transplantation conditioning regimen with high doses of chemotherapy/radiotherapy and to the infusion of donor T-cells within the graft, that mediate graft-versus-leukemia (GvL) effect [1].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: The Bottom Line Source Type: research
Condition:   Plasma Cell Leukemia Intervention:   Drug: Daratumumab Sponsor:   Assistance Publique - Hôpitaux de Paris Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Cancer J. 2021 May-Jun 01;27(3):196-200. doi: 10.1097/PPO.0000000000000520.ABSTRACTMultiple myeloma (MM), a plasma cell malignancy, accounts for ~10% of hematologic malignancies and predominantly affects the older population. It exhibits a heterogeneous biology and a complex genetic phenotype that affect patient prognosis. The treatment of MM has evolved significantly over the last decade with the use of autologous stem cell transplantation and several novel agents. Consequently, outcomes have improved in this time period, with the most impact in younger patients. Management of MM in elderly frail patients requires a thoug...
Source: Cancer Journal - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: Our study revealed that DOX suppressed chondrocyte differentiation by stimulating ROS production, providing a novel theoretical strategy for the clinical treatment of OA caused by DOX.PMID:34547383 | DOI:10.1016/j.ejps.2021.106013
Source: European Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Authors: Source Type: research
We describe a rare case of a 70-year-old man presenting with MS of the urinary bladder complicating known secondary AML (RUNX1 and IDH2 mutated). Prior to development of bladder MS, the patient had received decitabine, enasidenib, and venetoclax. Following diagnosis, he was treated with cytarabine and venetoclax. To our knowledge, this is the first case of bladder MS treated with a BCL-2 inhibitor.Case Rep Oncol 2021;14:1366 –1372
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Paediatr Drugs. 2021 Sep 20. doi: 10.1007/s40272-021-00469-9. Online ahead of print.ABSTRACTNeuroblastoma is the most common extracranial solid tumour in children, accounting for 15% of all paediatric cancer deaths. High-risk neuroblastoma is a particularly challenging-to-treat form of disease that requires multimodality treatment, consisting of chemotherapy, surgery, high-dose chemotherapy with autologous haematopoietic stem cell rescue, radiotherapy and differentiation therapy. However, despite intense multimodal treatment regimens, the prognosis for this patient population remains poor. In recent years, immunotherapy wi...
Source: Paediatric Drugs - Category: Pediatrics Authors: Source Type: research
More News: Biology | Chemotherapy | Cytology | International Medicine & Public Health | Stem Cell Therapy | Stem Cells | Study